CSIMarket Company Name, Ticker, Competitors, else..
 
Inogen Inc   (INGN)
Other Ticker:  
 
 
Price: $6.0300 $0.24 4.145%
Day's High: $6.04 Week Perf: 5.05 %
Day's Low: $ 5.80 30 Day Perf: 33.41 %
Volume (M): 239 52 Wk High: $ 26.11
Volume (M$): $ 1,441 52 Wk Avg: $12.20
Open: $5.81 52 Wk Low: $4.13



 Market Capitalization (Millions $) 140
 Shares Outstanding (Millions) 23
 Employees 872
 Revenues (TTM) (Millions $) 328
 Net Income (TTM) (Millions $) -133
 Cash Flow (TTM) (Millions $) -85
 Capital Exp. (TTM) (Millions $) 5

Inogen Inc
Inogen Inc is a medical device company that specializes in the development and manufacturing of portable oxygen concentrators (POCs) for patients suffering from respiratory diseases such as chronic obstructive pulmonary disease (COPD), emphysema, and pulmonary fibrosis.
The company was founded in 2001 and is headquartered in Goleta, California.
Inogen's POCs are designed to provide patients with greater mobility, independence, and quality of life.
Unlike traditional oxygen therapy methods such as oxygen cylinders, Inogen's POCs are lightweight, compact, and can be worn on the patient's body, allowing them to travel and participate in daily activities without being constrained by bulky equipment.
In addition to POCs, the company also offers a range of accessories such as replacement batteries, carrying cases, and extra cannulas.
Inogen's products are sold directly to patients as well as through a network of authorized dealers and distributors in the US and internationally.
Inogen's innovative products and focus on patient needs have earned it numerous awards and accolades, including being named one of Forbes' "Most Innovative Growth Companies" and Medical Design Briefs' "2016 Medical Product of the Year."


   Company Address: 859 Ward Drive Goleta 93111 CA
   Company Phone Number: 562-0500   Stock Exchange / Ticker: NASDAQ INGN
   INGN is expected to report next financial results on February 23, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Nocturne Acquisition Corporation

MBTCUs Scores Big in Third Quarter of 2023, Replicating Last Year's Success



Nocturne Acquisition Corporation, a reputable player in the financial industry, recently announced its earnings for the third quarter of 2023. While the results indicate increased deficits per share compared to the previous year, it is important to consider the broader context and acknowledge positive shifts that may impact future financial performance. This article will explore the implications of these results and shed light on the potential for a bullish outlook for Nocturne Acquisition Corporation.
Increased Deficits Per Share:
The most notable aspect of the Q3 2023 earnings report is the increase in deficits per share. Nocturne Acquisition Corporation experienced a deficit per share of $-0.11, as opposed to $-0.03 from the preceding year. This indicates a decline in profitability on a per-share basis. Additionally, the deficit grew from $-0.02 per share in the preceding reporting season. These numbers suggest that Nocturne Acquisition Corporation faced challenges during this period.
Becton Dickinson And Company

Medical Equipment and Supplies Company Witnesses Alarming Plunge in Earnings per Share Amidst Recent Fiscal Period

Becton Dickinson And Company, a medical equipment and supplies company, recently released its financial results for the fourth quarter of 2023. The company reported an income per share of $0.37 and revenue of $4.88 billion during this period. While the revenue increased by 20.459% compared to the fourth quarter of 2022, the company's income per share declined from $0.92 to $0.37. This indicates that although Becton Dickinson And Company saw significant revenue growth, their profitability decreased.
However, when compared to other companies in the Medical Equipment and Supplies sector, Becton Dickinson And Company had a much higher top-line improvement during the fourth quarter of 2023. On average, companies in this sector reported a top-line improvement of 4.80% in comparison to the same period in 2022. In contrast, Becton Dickinson And Company experienced a revenue surge of 20.459%. This suggests that the company outperformed its industry peers in terms of revenue growth.
Iridex Corp

IRIX Triumphs Over Obstacles, Shines in Q3 Earnings Season

Iridex Corp, a leading medical equipment and supplies company, recently released its financial results for the third quarter of 2023 earnings season. While the company reported a net loss of $-0.11 per share, this is an improvement compared to the previous year's loss of $-0.17 per share. However, the revenue for the quarter declined significantly by -12.718% to $12.62 million, compared to $14.46 million in the same period a year ago.
This decline in revenue is in stark contrast to the overall trend in the Medical Equipment and Supplies sector, which saw a top-line gain during the same period. The company's management has not provided specific reasons for this decline, but some experts speculate that it may be due to slowing demand or other market factors.
Digital Health Acquisition Corp

Breaking News: Medical Equipment Company Minimizes Losses, Records Remarkable Progress with $-1.13M in Recent Fiscal Period

/>In the medical equipment and supplies sector, industry analysts are closely scrutinizing the third quarter financial performance of Digital Health Acquisition Corp (DHAC). With a reported operating loss of $-0.518084 million, the company has yet to disclose any top-line figures for the July to September 2023 reporting season. However, the current results reflect a significant improvement compared to the same period in 2022, where the operating loss stood at $-1.129361 million. This development serves as a key indicator for the company's overall situation.
Growing Importance of Cost-Effectiveness in the Market:
For emerging growth entities such as DHAC, developing sustainable revenue sources is crucial to advancing to the next phase. Consequently, cost-effectiveness has become a vital aspect for these companies to remain competitive in the industry. Despite DHAC's efforts to prompt revenue sources, it is noteworthy that the company achieved not only a net profit of $0.078 million but also outperformed its Q3 2022 results.
Nuo Therapeutics Inc

Strong Third-Quarter Performance Positions Nuo Therapeutics Inc. as a Dominant Player in Medical Equipment and Supplies Industry

Nuo Therapeutics Inc: A Bullish Outlook for Future Growth
Nuo Therapeutics Inc, a leading Medical Equipment and Supplies company, recently reported third-quarter earnings that exceeded industry expectations. With a remarkable revenue rise of 507.166% year on year to $0.23 million, Nuo Therapeutics has demonstrated its robustness and resilience in the market. Although the company experienced a loss at $-0.02 per share, its strong revenue growth far outweighs this setback.
When compared to its industry peers, Nuo Therapeutics has clearly outperformed. The Medical Equipment and Supplies industry, as a whole, has averaged a revenue increase of just 4.80% during the same period. This significant gap in revenue growth showcases Nuo Therapeutics' ability to outshine its competitors and solidify its position as a market leader.





 

Inogen Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com